Edition:
United States

InVivo Therapeutics Holdings Corp (NVIV.OQ)

NVIV.OQ on NASDAQ Stock Exchange Capital Market

4.60USD
4:00pm EDT
Change (% chg)

$-0.22 (-4.56%)
Prev Close
$4.82
Open
$4.76
Day's High
$5.12
Day's Low
$4.39
Volume
34,695
Avg. Vol
19,134
52-wk High
$96.25
52-wk Low
$4.39

Chart for

About

InVivo Therapeutics Holdings Corp., formerly Design Source, Inc., is a research and clinical-stage biomaterials and biotechnology company. The Company is engaged in developing and commercializing biopolymer-scaffolding devices for the treatment of spinal cord injuries (SCI). The Company's approach to treating acute SCIs is based... (more)

Overall

Beta: 2.51
Market Cap(Mil.): $9.08
Shares Outstanding(Mil.): 1.57
Dividend: --
Yield (%): --

Financials

  NVIV.OQ Industry Sector
P/E (TTM): -- 38.13 34.14
EPS (TTM): -98.78 -- --
ROI: -147.75 8.73 13.17
ROE: -155.69 12.61 15.14

BRIEF-Invivo Therapeutics Reports Q1 Loss Per Share Of $3.34

* INVIVO THERAPEUTICS REPORTS 2018 FIRST QUARTER FINANCIAL RESULTS

May 07 2018

BRIEF-Invivo Therapeutics Files For Offering Of Up To $8 Mln Shares

* INVIVO THERAPEUTICS HOLDINGS CORP FILES FOR OFFERING OF UP TO $8 MILLION SHARES OF COMMON STOCK, WARRANTS TO PURCHASE SHARES OF COMMON STOCK - SEC FILING Source text (https://bit.ly/2HrYEIM) Further company coverage:

Apr 24 2018

BRIEF-Invivo Therapeutics Announces Reverse Stock Split

* ANTICIPATES REVERSE STOCK SPLIT WILL BECOME EFFECTIVE AT 5:00 P.M. EASTERN TIME ON APRIL 16, 2018

Apr 09 2018

BRIEF-Invivo Therapeutics Receives FDA Approval For Controlled Trial Of The Neuro-Spinal Scaffold™

* INVIVO THERAPEUTICS RECEIVES FDA APPROVAL FOR PIVOTAL, RANDOMIZED, CONTROLLED TRIAL OF THE NEURO-SPINAL SCAFFOLD™ IN PATIENTS WITH ACUTE SPINAL CORD INJURY Source text for Eikon: Further company coverage: (Reuters.Brief@thomsonreuters.com)

Mar 08 2018

BRIEF-InVivo Therapeutics Appoints Richard Toselli As Chief Executive Officer

* INVIVO THERAPEUTICS ANNOUNCES APPOINTMENT OF RICHARD TOSELLI, M.D., AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

Feb 05 2018

BRIEF-Invivo Therapeutics Says There Is Substantial Doubt About Ability To Continue As A Going Concern

* INVIVO THERAPEUTICS SAYS "THERE IS SUBSTANTIAL DOUBT ABOUT OUR ABILITY TO CONTINUE AS A GOING CONCERN" - SEC FILING

Jan 29 2018

BRIEF-Invivo Therapeutics Announces Purchase Agreement For Up To $15 Mln With Lincoln Park Capital

* INVIVO THERAPEUTICS ANNOUNCES PURCHASE AGREEMENT FOR UP TO $15 MILLION WITH LINCOLN PARK CAPITAL

Jan 26 2018

BRIEF-InVivo Therapeutics Announces Latest Results From INSPIRE

* INVIVO THERAPEUTICS ANNOUNCES LATEST RESULTS FROM INSPIRE AND PROVIDES UPDATE ON PROPOSED CLINICAL PATH FORWARD

Jan 03 2018

Earnings vs. Estimates